Close Menu

Evotec

The high-throughput and assay development agreement will focus on identifying and validating hits for an immune disease and cancer-related target.

Kinaxo’s phosphoproteomic tools will support targeted treatment development at Roche.

The German biotech plans to invest €3 million to €4 million in biomarker development over the next two years.

Movers & Shakers: Nov 20, 2009

Premium

Christian Jurinke, Jeff Protentis, Jürgen Schumacher

In addition to biomarker discovery, Kinaxo's PhosphoScout technology will be used to assess the anti-cancer drug Nexavar's effects on cellular phosphorylation patterns.

Kinaxo Biotechnologies and Bayer Vital announced that they are collaborating to identify novel cancer treatment biomarkers.

The companies have extended one agreement and formed another focused on bringing an Ono compound towards clinical development.

New Products: Oct 1, 2009

Premium

Agilent Technologies, Bio-Rad, Bruker, Pressure BioScieces, Thermo Fisher Scientific, Pheonomenex, Kinaxo

Evotec will screen a target and develop assays for Biogen Idec.

Pages

Nature News reports on the US National Science Foundation's investigations of undisclosed foreign ties among researchers it funds.

Researchers have developed a set of 10 principles to guide how a list of all species on earth should be put together, the Guardian reports.

Wired reports on a new firm developing a gene writing approach for therapeutic genome changes.

In Nature this week: a method called cis-X combines whole-genome and transcriptome sequencing data to identify regulatory noncoding variants, and more.